Ken Griffin Arca Biopharma, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$1.71 - $4.0 $55,746 - $130,400	-32,600 Reduced 59.6%	22,100 $84,000
Q1 2024 May 15, 2024	BUY	$1.58 - $1.78 $77,104 - $86,864	48,800 Added 827.12%	54,700 $96,000
Q4 2023 Feb 14, 2024	SELL	$1.7 - $2.05 $8,160 - $9,840	-4,800 Reduced 44.86%	5,900 $10,000
Q3 2023 Nov 14, 2023	SELL	$2.01 - $2.07 $6,833 - $7,037	-3,400 Reduced 24.11%	10,700 $21,000
Q2 2023 Aug 14, 2023	BUY	$1.94 - $2.11 $10,476 - $11,394	5,400 Added 62.07%	14,100 $28,000
Q1 2023 May 15, 2023	SELL	$1.99 - $2.55 $7,363 - $9,435	-3,700 Reduced 29.84%	8,700 $17,000
Q4 2022 Feb 14, 2023	BUY	$1.86 - $25.8 $23,064 - $319,920	12,400 New	12,400 $29,000

280K

Ticker ABIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,410,100
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.